Sector News

Five Prime names ex-Genentech I-O specialist research SVP

August 21, 2017
Life sciences

Five Prime Therapeutics has appointed Bryan Irving, Ph.D., as its SVP of research. Irving made his name in the industry in a decadelong stint at Genentech, during which he performed research that gave rise to anti-PD-L1 antibody Tecentriq.

South San Francisco, CA-based Five Prime landed Irving after persuading him to swap a VP position at neighboring CytomX Therapeutics for a chance to lead its research effort. Irving spent 4 years in roles of increasing responsibility at CytomX. But unless that work results in a major product, he will remain best known for his research at a company whose buildings are all around those of his current and former employer: Genentech.

Irving swapped an academic career in which he helped develop CAR technology for a role at Genentech in 2001, initially to study lupus and Type 1 diabetes. After 4 years, Irving pivoted to research tumor-specific T cells, leading him to file a patent on the use of anti-PD-L1 antibodies to enhance the function of T cells.

That work ultimately led to Tecentriq, the late-to-the-party anti-PD-L1 drug Genentech and parent company Roche see as the cornerstone of their immuno-oncology plans.

Management at Five Prime is now looking to Irving to unearth similar successes from its research platform.

“Five Prime has built an unparalleled proprietary library of more than 5,700 human extracellular proteins containing the majority of medically relevant protein drug targets. I look forward to applying my experience in immuno-oncology to this platform in an effort to identify new targets, which could translate into multiple therapeutic proteins,” Irving said in a statement.

Irving replaces Luis Borges, Ph.D. Borges joined Five Prime as senior director in 2014 after 12 years at Amgen, after which a series of promotions led him to take the SVP of research post 11 months ago. Five Prime listed Borges as holding the SVP post as recently as August 12. But his name has now vanished from the management roster and is absent from the release unveiling the appointment of Irving.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach